Related references
Note: Only part of the references are listed.Eosinophilic and Noneosinophilic Asthma
Tara F. Carr et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab
Manali Mukherjee et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Sputum autoantibodies in patients with severe eosinophilic asthma
Manali Mukherjee et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Biologic Therapy and Novel Molecular Targets of Severe Asthma
Amber N. Pepper et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
Leif Bjermer et al.
CHEST (2016)
Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma
R. Sehmi et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2016)
Treatable traits: toward precision medicine of chronic airway diseases
Alvar Agusti et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5R, in Uncontrolled Eosinophilic Asthma
MirHojjat Khorasanizadeh et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2016)
Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia
Steven G. Smith et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum
Astrid Crespo et al.
JOURNAL OF ASTHMA (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
Hector G. Ortega et al.
LANCET RESPIRATORY MEDICINE (2016)
Improving the diagnosis of eosinophilic asthma
Hanneke Coumou et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2016)
Severe asthma: anti-IgE or anti-IL-5?
Evgenia Papathanassiou et al.
EUROPEAN CLINICAL RESPIRATORY JOURNAL (2016)
Targeting the interleukin pathway in the treatment of asthma
Kian Fan Chung
LANCET (2015)
Blood or sputum eosinophils to guide asthma therapy?
Manali Mukherjee et al.
LANCET RESPIRATORY MEDICINE (2015)
Biologics in Asthma-The Next Step Toward Personalized Treatment
Jared Darveaux et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2015)
Primary lysis of eosinophils in severe desquamative asthma
C. Persson
CLINICAL AND EXPERIMENTAL ALLERGY (2014)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
Pranabashis Haldar et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Anti-Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma
Parameswaran Nair
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Current evidence and future research needs for FeNO measurement in respiratory diseases
Leif Bjermer et al.
RESPIRATORY MEDICINE (2014)
Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia
P. Nair et al.
ALLERGY (2013)
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
Michel Laviolette et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications
Raed A. Dweik et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
Jan Lotvall et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
William W. Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Glucocorticoid resistance in inflammatory diseases
Peter J. Barnes et al.
LANCET (2009)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma
Patrick Flood-Page et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Anti-eosinophil peroxidase antibodies detected in patients with primary biliary cirrhosis
J Takiguchi et al.
HEPATOLOGY RESEARCH (2005)
The global burden of asthma: executive summary of the GINA Dissemination Committee Report
M Masoli et al.
ALLERGY (2004)
Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma - A pilot study 164/rccm.200206-5250C
JC Kips et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
MJ Leckie et al.
LANCET (2000)
Share Paper
